Ameriprise
FHTX icon

Ameriprise’s Foghorn Therapeutics FHTX Stock Holding History

Ameriprise’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.15M Sell
448,976
-158,694
-26% -$871K ﹤0.01% 2926
2025
Q4 		$3.28M Buy
+607,670
New +$2.75M ﹤0.01% 2737
2025
Q3 		– Sell
-112,237
Closed -$528K – 4096
2025
Q2 		$528K Buy
+112,237
New +$469K ﹤0.01% 3511

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Ameriprise's FHTX Position: Q1 2026 in Review

Ameriprise reduced its Foghorn Therapeutics (FHTX) stake by 26% in Q1 2026, selling an estimated $871K and leaving 448,976 shares worth $2.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2926.

Ameriprise first reported a position in FHTX in Q2 2025 and has held it in 3 quarters since. The position peaked at $3.28M in Q4 2025. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Ameriprise held 448,976 shares of Foghorn Therapeutics worth $2.15M as of Q1 2026.
  • Ameriprise sold 158,694 Foghorn Therapeutics shares in Q1 2026, an estimated $871K.
  • Foghorn Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2926 holding.
  • Ameriprise first reported a position in Foghorn Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Ameriprise's Foghorn Therapeutics position peaked at $3.28M in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.